GlassScriptPhysician profile
Ahmed Hussain
NPI 1407936974
$3,669.95
in general payments reported to CMS, 2019-2025
34 companies · $788 in 2025
The $788 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $496 · 2021: $202 · 2022: $170 · 2023: $311 · 2024: $598 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $368.50 | 2020-2024 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.71 | 2019-2025 | Xifaxan |
| Pfizer INC. | $318.70 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $280.59 | 2019-2024 | Xarelto |
| Inspire Medical Systems, INC. | $250.46 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $180.22 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $176.01 | 2019-2025 | Eliquis |
| Astellas Pharma US INC | $160.28 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $136.35 | 2025 | Zenpep |
| Kestra Medical Technology Services, INC. | $90.24 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.54 | 2019-2020 | |
| Amgen INC. | $82.51 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $72.57 | 2025 | |
| Exact Sciences Corporation | $65.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $61.80 | 2019 | |
| Dexcom, INC. | $60.10 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $46.53 | 2019-2021 | |
| Biosense Webster, INC. | $46.23 | 2025 | Carto 3 |
| Abbott Laboratories | $40.07 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $35.29 | 2025 | Uzedy |
| Corcept Therapeutics | $29.44 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $27.81 | 2019 | |
| Lilly USA, LLC | $25.76 | 2019 | |
| Sumitomo Pharma America, INC. | $23.42 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $22.15 | 2024 | |
| Redhill Biopharma INC. | $18.44 | 2020 | |
| Advanced Respiratory, INC | $18.06 | 2020 | |
| Merck Sharp & Dohme LLC | $17.85 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.49 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.79 | 2025 | |
| Allergan, INC. | $14.37 | 2019 | |
| Orthogenrx INC. | $12.90 | 2020 | |
| Hikma Pharmaceuticals USA | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.